RPID

SEC source: 0000899243-21-029222 · doc4.xml · derivative · entry 5

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,334,562 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.

F7 · ownership.nature: Jeffrey Schwartz is a director of the Issuer.

SEC source: 0000899243-21-029222 · doc4.xml · derivative · entry 4

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Class A Common Stock · 6,999,998 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.

F7 · ownership.nature: Jeffrey Schwartz is a director of the Issuer.

SEC source: 0000899243-21-029222 · doc4.xml · nonDerivative · entry 3

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,434,560

F4 · ownership.nature: Represents 90,714 and 9,286 shares of the Issuer's Class A Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.

F7 · ownership.nature: Jeffrey Schwartz is a director of the Issuer.

SEC source: 0000899243-21-029222 · doc4.xml · nonDerivative · entry 2

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,334,560

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS, which were automatically converted into 1,210,642 and 123,920 shares of the Issuer's Class A Common stock, respectively, immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.

F7 · ownership.nature: Jeffrey Schwartz is a director of the Issuer.

SEC source: 0000899243-21-029222 · doc4.xml · nonDerivative · entry 1

Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner

Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner

Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner

BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

Koppel Adam · CIK 0001578965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 6,999,998

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock automatically converted into 0.2 of a share of the Issuer's Class A Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"), which were automatically converted into 6,350,013 and 649,985 shares of the Issuer's Class A Common Stock, respectively, immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.

F7 · ownership.nature: Jeffrey Schwartz is a director of the Issuer.

SEC source: 0001104659-21-092762 · tm2122156-18_4seq1.xml · derivative · entry 1

RICCIARDI NATALE S · CIK 0001107158 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001104659-21-092760 · tm2122156-16_4seq1.xml · derivative · entry 1

Schmitz Alexander · CIK 0001853566 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001104659-21-092761 · tm2122156-17_4seq1.xml · derivative · entry 1

PEI MELINDA LITHERLAND · CIK 0001703469 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001104659-21-092759 · tm2122156-15_4seq1.xml · derivative · entry 1

Kollender Richard S · CIK 0001415666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001104659-21-092758 · tm2122156-14_4seq1.xml · derivative · entry 1

Hirsch David · CIK 0001619884 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0000899243-21-028644 · doc4.xml · derivative · entry 1

Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-07-13

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021.

SEC source: 0001104659-21-152314 · tm2136069-2_4seq1.xml · derivative · entry 1

LOWENSTEIN INESE · CIK 0001900476 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2031-12-17

F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on January 17, 2021.